33,500 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,500 shares of the company’s stock, valued at approximately $234,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth $25,000. Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the period. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. KBC Group NV lifted its position in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Finally, Amalgamated Bank lifted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $7.13 on Thursday. The stock has a 50-day simple moving average of $6.59 and a 200 day simple moving average of $7.35. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -4.66 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the firm earned ($0.43) earnings per share. The business’s quarterly revenue was up 147.6% compared to the same quarter last year. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of analyst reports. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.25.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock valued at $895,538 over the last ninety days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.